In an Intech article, Three strategies help life sciences companies implement more successful review by exception, Emerson’s Emilee Cook shares ways for these manufacturers to improve this workflow.
Imagine driving the wrong direction for hundreds of miles after a wrong turn, simply because you didn’t notice missing the exit. Overlooked deviations can cause a lot of frustration, whether during a drive or while executing a batch of pharmaceuticals. Detecting and...
At the Biomanufacturing World Summit, Emerson’s Ron Rossbach presented on using digitalization and data integration to help drive operational efficiency. A key enabling technology for these performance gains is in real-time adaptive scheduling. This technology combines finite scheduling with dynamic updates from existing shop-floor execution systems to optimize operations. In 2018 Emerson acquired BioG, the leading provider of adaptive scheduling software, which is now being adopted across the industry.
The U.S. Food & Drug Administration (FDA) outlines the drug development process in five steps: Discovery and development Preclinical research Clinical trials FDA review FDA post-market safety monitoring I caught up with Emerson's Zuwei Jin whom you may recall from...
In this 2:25 YouTube video, Address Cell Therapy Batch Production Challenges with Syncade, Emerson’s Michalle Adkins shares how operations management technology plays an important role in addressing these challenges.
Author: Jonathan Lustri I have previously been interviewed and written about a process control and MES [Manufacturing Execution Systems] architecture where the batch control logic within the process control system is the single procedural engine. It drives procedural...
Yesterday we highlighted advancements in exception management technology for pharmaceutical and biopharmaceutical manufacturers. Exception management is one element in an electronic batch record (EBR). Other elements for the EBR which also have high data integrity...
Exceptions in batch manufacturing processes are the deviations that occur outside the prescribed specifications. For pharmaceutical and biopharmaceutical manufacturers, quality and manufacturing personnel must review these exceptions. Traditionally, this quality...
We conclude our series on improving cell therapy manufacturing with a closer look at the review by exception process. In the manufacturing process of cell therapeutics, product cycle times are extremely short and any exceptions occurring during the production process...
Pharmaceutical and biotech manufacturers seek to improve both project and operational performance through implementation of smart factory technology. The smart factory fits right into the S95 enterprise automation model and provides out-of-box manufacturing...
Manufacturing processes have long been paper-based with log entries, initialing, signoffs and other transactions to manually record. While automation systems have captured some of this manual recordkeeping, they have not been able to capture everything. In batch...
In an earlier post, Managing the Chain of Identity in Cell Therapeutics Manufacturing, we highlighted how the manufacturing process of these cell therapies must be performed with absolute accuracy the first time since each batch is produced for a specific patient....
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to keep up to date on all the latest news, events and innovations to help you take on and solve your toughest challenges.
Please do, Just link back to the post and send us a quick note so we can share your work. Thanks!
Our Global Community
The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.